Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

Kyntra's prostate exit shows how thin the funding runway is for a biotech that has to reset

After a Phase 2 interim miss, Kyntra Bio is cutting its royalty-financing cap and pivoting to roxadustat in MDS, and its plan is subject to funding in a split biotech capital market.

18 Nov 2026 · CompePharma editorial

What happened

Kyntra Bio (KYNB) said on November 16 that it is halting work on FG-3246 and a second prostate cancer candidate after a Phase 2 interim analysis showed insufficient efficacy. The company is refocusing on roxadustat in lower-risk myelodysplastic syndromes (MDS) and plans a Phase 3 trial there, 'subject to funding'. It is also cutting the cap on its royalty financing. Our source material does not give the size of the reduction or the counterparty terms, so we do not speculate on either.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →